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Abstract
Background: Astrocytomas are cancers of the brain in which high levels of extracellular glutamate plays a critical
role in tumor growth and resistance to conventional treatments. This is due for part to a decrease in the activity of
the glutamate transporters, i.e. the Excitatory Amino Acid Transporters or EAATs, in relation to their nuclear
mislocalization in astrocytoma cells. Although non-astrocytoma cancers express EAATs, the localization of EAATs
and the handling of L-glutamate in that case have not been investigated.
Methods: We looked at the cellular localization and activity of EAATs in human astrocytoma and non-astrocytoma
cancer cells by immunofluorescence, cell fractionation and L-glutamate transport studies.
Results: We demonstrated that the nuclear mislocalization of EAATs was not restricted to astrocytoma and
happened in all sub-confluent non-astrocytoma cancer cells we tested. In addition, we found that cell-cell contact
caused the relocalization of EAATs from the nuclei to the plasma membrane in all human cancer cells tested,
except astrocytoma.
Conclusions: Taken together, our results demonstrated that the mislocalization of the EAATs and its associated
altered handling of glutamate are not restricted to astrocytomas but were also found in human non-astrocytoma
cancers. Importantly, we found that a cell contact-dependent signal caused the relocalization of EAATs at the
plasma membrane at least in human non-astrocytoma cancer cells, resulting in the correction of the altered
transport of glutamate in such cancer cells but not in astrocytoma.
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Background
Among adult brain tumors, gliomas are the most com-
mon form, accounting for more than 70% of the brain
cancer [1,2]. Gliomas arise from the malignant transfor-
mation of glial cells, mainly astrocytes, oligodendrocytes
and ependymal cells. Astrocytomas are the most fre-
quent and malignant form of gliomas and are associated
generally to a poor prognostic [1,2]. Thus, meta-analysis
have showed that 1 year survival rates of patients
affected by astrocytomas is around 40% and that con-
ventional treatments (i.e. surgery, radiotherapy and che-
motherapy) only slightly increase the survival (from 40
to 46%, respectively) [3].
In vivo and in vitro experiments have showed that the
growth, invasion and resistance to treatment of astrocy-
tomas are dependent of an altered handling of the gluta-
mate by malignant astrocytes [4-7] although other
factors, such as tissue hypoxia and modification of sur-
face antigens, could participate [8-11].
Physiologically, normal astrocytes are responsible for
the recapture of the glutamate released by glutaminergic
neurons during the synaptic communication. This
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any medium, provided the original work is properly cited.recapture is essential for the termination of the synaptic
transmission and to prevent neuronal damage caused by
high excitotoxic extracellular glutamate concentrations
[12]. Glutamate uptake by astrocytes takes place mainly
through two high affinity sodium-dependent excitatory
amino-acid transporters (EAAT), i.e. EAAT1/GLAST
and EAAT2/GLT-1, isoform’s expression by normal
astrocytes being specific of brain area [12]. Contrary to
normal astrocytes that absorb more glutamate than they
secrete it, malignant astrocytes are responsible for a
high secretion of glutamate at the vicinity of the tumor
[4,6,7]. This major difference in the handling of the glu-
tamate by normal and malignant astrocytes is due to
alterations of the activity/expression of glutamate trans-
porters, i.e. excitatory amino-acid transporters (EAATs)
and the cystine-glutamate exchanger (Xc
-). EAATs are
responsible for the absorption of glutamate whereas Xc
-
is involved in the secretion of glutamate and the entry
of L-cystine, a precursor of glutathione. In normal astro-
cytes the activity of EAATs is higher than the activity of
Xc
-, resulting in a net absorption of glutamate. Conver-
sely, malignant astrocytes display a defect in the EAAT-
dependent absorption of glutamate and an increase in
Xc
--dependent secretion of glutamate, causing the net
secretion of the excitatory amino-acid observed in astro-
cytomas. Previous study elegantly showed that the defect
of EAATs activity in human astrocytomas and all
human astrocytoma cell lines (including STTG-1 cells)
is due to the mislocalization of the transporters into the
nuclei [13]. Thus, EAATs were found in the nuclei of all
human astrocytoma cell lines tested and in astrocytoma
biopsies, making of STTG-1 a good in vitro model to
study EAATs mislocalisation in astrocytoma.
The resulting high extracellular concentration of gluta-
mate at the vicinity of the tumor has major implication
both in terms of pathophysiology and cancer biology
[4,6,7]. Thus, the glutamate secreted by astrocytomas
induces the death of normal brain cells surrounding the
tumor through activation of the ionotropic glutamate
receptor (NMDA) and excito-toxicity, making more
space for the tumor to expend. Secreted glutamate is also
responsible for epilepsy and other neurologic disorders
associated with astrocytomas. Moreover, the secretion of
glutamate by malignant astrocytes allows the entry of L-
cystine through the Xc
- exchanger, leading to an increase
in the intracellular concentration of glutathione and to
an increase in the resistance of astrocytomas to oxidative
stress caused by radiation or chemo-therapy. Finally, the
secreted glutamate stimulates the division of malignant
astrocytes by activating metabotropic glutamate transpor-
ters through para- and autocrine action [14].
Based on the high dependency of astrocytomas to
extracellular glutamate, new treatment strategies have
been developed to strike the tumors at the level of the
glutamate transporters and receptors. Thus, inhibitors of
Xc
- exchanger have been shown to decrease the growth,
invasion and the resistance of astrocytomas to radiation
and chemo-therapy by limiting the intracellular concen-
tration of glutathione [15]. Antagonists of metabotropic
glutamate receptors have been also used successfully to
limit the growth of astrocytomas by blocking the para-/
autocrine stimulation of the growth of tumor cells by
secreted glutamate [16,17]. However, to date, no strate-
gies have been developed to correct the defect of
EAATs-mediated absorption of glutamate observed in
human astrocytomas, the cellular or molecular event
responsible for the nuclear localization of EAATs being
still uncharacterised. Correcting the mislocalization of
EAATs will theoretically reverse the net secretion of
glutamate by malignant astrocytes into a net absorption
and thus will deprive the tumor of the extracellular glu-
tamate essential for its growth, invasion and resistance.
Although it has been demonstrated that cancer cells of
non-central nervous system origin also express EAATs
and could secrete glutamate through Xc
- activity [18,19],
the activity/localization of EAATs in non-astrocytoma
cancers were not evaluated. In the present study, we
looked at the cellular localization and activity of EAATs
in human cancer cells originating from various tissues
and found that the nuclear mislocalization of EAAT and
the associated altered glutamate handling are not limited
to astocytoma cancer and happens in many human can-
cer cells. We also found that the mislocalization of
EAATs could be corrected by cell contact in all human
cancer cells tested, except astrocytoma.
Methods
Ethical treatment of animals
All work involving animal have been conducted in
accordance with the European Communities Council
Directive of 24 November 1986 (86/609/EEC) and with
the local committee’s recommendations (C-13-055-6,
Aix-Marseille University).
Human cancer cells and primary cell cultures
Human cells used in this study are summarized in Table 1.
All cells were from ATCC, except SH-SY5Y and STTG-1
Table 1 List of human cancer cells used in this study.
Name ATCC number Cancer type Organ/cell type
AGS CRL-1739 Adenocarcinoma Stomach/Epithelial cell
Caco-2 HTB-37 Adenocarcinoma Colon/Epithelial cell
HeLa CCL-2 Adenocarcinoma Cervix/Epithelial cell
HOG - Oligodendrocytoma Brain/Oligodendrocyte
HT-29 HTB-38 Adenocarcinoma Colon/Epithelial cell
SH-SY5Y CRL-2266 Neuroblastoma Brain/Neuron
STTG1 CRL-1718 Astrocytoma Brain/Astrocyte
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which were initially isolated from a surgically removed
human oligodendroglioma [20] and that were kindly pro-
vided by Drs. López-Guerrero and Bello-Morales (CSIC-
UAM, Cantoblanco, Madrid, Spain). All human cells were
routinely cultured on 75 cm
2 flasks in Dulbecco’s modified
essential medium (DMEM) supplemented with 2 mM glu-
tamine, 10% (v:v) fetal calf serum (FCS) and 100 μg/mL
streptomycin and 100 U/mL penicillin. Flasks were main-
tained in a humidified incubator at 37°C with 95% air and
5% CO2. Primary cultures of cortical astrocytes were pre-
pared from new born rats as previously described [21,22].
Immunofluorescence microscopy and image analysis
Cells were seeded onto glass coverslips at an initial cell
density of 100,000 cells per cm
2. Sub-confluent (typically
1-2 days after seeding) and confluent cells (typically 7-
10 days post-seeding) were washed once time in phos-
phate buffer saline (PBS) and were fixed for 10 min at
room temperature with 4% paraformaldehyde diluted in
PBS. Coverslips were then washed three times in PBS
and incubated for 1 h at room temperature in satura-
tion/permeabilisation buffer containing 2% (w:v) bovine
serum albumin and 0.1% Triton X-100 diluted in PBS.
After three washes with PBS, primary antibodies direc-
ted against EAAT1/GLAST or EAAT2/GLT-1 (diluted
in PBS according to manufacturers) were added for 1 h
at room temperature. Primary antibodies used in this
study were goat anti-EAAT1 (AB1782) and anti-EAAT2
(AB1783), obtained from Chemicon, directed against
amino-acids from the C-terminal part of EAAT1 or 2,
and rabbit anti-EAAT1 (sc-15316) and anti-EAAT2 (sc-
15317) obtained from Santa Cruz and directed against
amino-acids from the N-terminal part of EAAT1 or 2.
Cells were also stained with primary antibodies (all from
Santa Cruz) directed other antigens specific of particular
cell compartments according to manufacturer instruc-
tions. After three washes with PBS, primary antibodies
were detected using specific secondary antibodies conju-
gated to Alexa-488 (Invitrogen) (1:200 dilution in PBS)
for 1 h at room temperature. In some cases, actin was
stained using phalloidin-TRITC (Sigma, diluted 1:2000).
Finally, coverslips were washed six times with PBS and
were mounted in Vectashield medium containing the
nuclear stain DAPI, sealed with nail varnish and viewed
using a fluorescence microscope (Leica). Fluorescence
intensity determination and image analysis were per-
formed using Image J (NIH) and measured as arbitrary
fluorescence values based on the mean numbers of pix-
els for each channel. After background subtraction, total
fluorescence from individual cells and from nuclei were
determined as a region of interest (ROI) using Image J
software. The nuclear signal was directly measured by
making an ROI around the nuclei whereas total cell
fluorescence was measured by making an ROI around
the whole cells. At least 100 different cells were analysed
per conditions. Negative control slides not incubated
with primary antibodies were used to set base para-
meters for each series of slides, which was maintained
during visualisation, ensuring the detected signal was
specific.
Cell fractionation and western-blot analysis
Cellular localization of EAATs was studied using deter-
gent-based cell fractionation kit from Pierce. Cells were
seeded onto 10 cm
2 plastic Petri dishes and cell fractio-
nation was done according to manufacturer. Briefly,
attached cells were washed three time with ice-cold PBS
++ and then scraped in ice-cold PBS. Cells were trans-
ferred in microcentrifuge tubes and pelleted by centrifu-
gation at 500 × g for 5 min. Supernatants were
eliminated and cell pellets were resuspended in ice-cold
cytosolic extraction buffer (CEB, Pierce). After 10 min
at 4°C, tubes were centrifuged at 500 × g for 5 min.
Supernatants (corresponding to cytosolic fractions) were
collected. Pellets were resuspended in membrane extrac-
tion buffer (MEB, Pierce), vortexed and left 10 min at 4°
C. Tubes were then centrifuged at 3000 × g for 5 min.
Supernatants (corresponding to membrane fractions)
were collected and pellets were resuspended in nuclear
extraction buffer (NEB, Pierce), giving the nuclear frac-
tion. Fractions corresponding to cytosol, membrane and
nuclei were boiled 5 min at 95°C in the presence of
Laemmlli sample buffer. Fractions were then subjected
to SDS-PAGE on 10% polyacrylamide gels and trans-
ferred onto nitrocellulose membranes. The membranes
were saturated for 1 h at room temperature with satura-
tion buffer (PBS containing 5% non-fat dried milk).
After one wash with washing buffer (PBS supplemented
with 0.1% Tween-20), membranes were incubated for 1
h with the appropriate primary antibody diluted in
saturation buffer according to manufacturer’s sugges-
tions. After three washes with washing buffer, mem-
branes were incubated for 1 h at room temperature with
secondary antibody conjugated to alkaline phosphatase
(from Jackson Immunoresearch) diluted in saturation
buffer. Finally, membranes were washed six times and
the immune complexes were detected using alkaline
phosphatase substrate (NBT/BCIP from Pierce). The
purity of each fractions and the absence of cross-con-
taminations were always assessed using antibodies direc-
ted against markers of each compartment (Hsp90, EGF-
R and Histone H3, respectively).
Measurement of the transport of glutamate
Cells originating from 75 cm
2 flasks were seeded onto
12-well CellBind™ plates at an initial density of 100.000
cells per cm
2. The uptake, the secretion and the net
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or confluent cells. Concentration of L-glutamate was
measured using enzymatic quantification. The uptake of
L-glutamate was measured as previously described
[21,22]. Briefly, cells were washed with warmed Hank’s
balanced salt solution (HBSS; pH 7.4) supplemented
with 10 mM D-glucose. After equilibration (15 min at
37°C in the CO2 incubator), medium was aspirated and
500 μL of HBBS + D-Glc containing 100 μM of L-gluta-
mate was added. After 60 minutes at 37°C, media were
collected and the residual extracellular glutamate con-
centrations measured using the enzymatic quantification
kit (Amplex
® red glutamate assay from Invitrogen)
[21,22]. Glutamate secretion was measured in DMEM
medium containing L-cystine (200 μM) but no phenol
red or glutamate. Cells were incubated for 6 h at 37°C
in the CO2 incubator before extracellular glutamate con-
centration was enzymatically measured. Both uptake and
secretion of L-glutamate were normalized using protein
content of the wells determined by the Folin procedure
[23]. Finally, the net transport of glutamate resulting
from the activity of EAATs and Xc
- was also measured.
In that case, cells seeded onto 12-well CellBind™ plates
were incubated at 37°C in the CO2 incubator with 500
μL of DMEM medium without phenol red but with L-
cystine (200 μM) and L-glutamate (100 μM). After 6 h
of incubation, media were collected and the concentra-
tions of glutamate were measured as described above.
Statistical analysis
t-Test was used to address the significant differences
between mean values with significance set at p <0 . 0 5
(GraphPad
® Prism5 software).
Results
Localization of EAATs in human astrocytoma and primary
astrocytes
STTG-1 cells were used to study EAATs localization in
human astrocytomas as it was already demonstrated
that this cell line perfectly mimics in vivo situation and
is a valuable model of human astrocytomas [13]. Immu-
nofluorescence (IF) microscopy, cell fractionation and
transport studies confirmed that EAATs were associated
with the nuclei in sub-confluent STTG-1 cells. Thus, IF
results demonstrated that most of the EAATs signal co-
localised with DAPI (Figure 1 and 2B). Changing the
primary (directed against the N or the C-terminal part
of EAATs) and secondary antibodies (directed against
guinea pig or rabbit primary antibodies) did not signifi-
cantly modify the co-localization of EAATs with DAPI
(Figure 1). The immunostaining of EAATs in normal
brain astrocytes furthermore confirmed that the aber-
rant localization of EAATs was restricted to malignant
astrocytes (Figure 2). Finally, we labelled antigens
specific of different cellular compartments: the cell
membrane (i.e. EGF receptor), the cytosol (i.e. actin)
and the nucleus (i.e. the transcription factor SP-1 and
Histone 3) (data not shown). As expected, only histone
3 and SP-1 were mostly associated to the nuclei as
demonstrated by the co-localization of histone 3/SP-1
and DAPI staining.
Cell fractionation and western analysis confirmed the
IF observations (Figure 3). Results demonstrated that
EAATs were mainly associated to the membrane frac-
tion and the nuclear fraction in primary astrocytes and
STTG-1 cells, respectively.
Finally, EAATs mislocalization in human astrocytoma
was demonstrated using transport studies (Table 2 and 3).
Thus, the uptake of glutamate by sub-confluent STTG-1
10 μm 
A 
C 
E 
G 
B 
D 
F 
H 
Figure 1 Immunostaining of EAATs in sub-confluent human
astrocytoma cells. Sub-confluent STTG-1 cells were labelled for
EAAT1/GLAST (A, B and E, F) or EAAT2/GLT-1 (C, D and G, H) using
primary antibodies obtained from Santa Cruz (directed against
N-terminal part of GLAST or GLT-1) (A and C) or from Chemicon
(directed against the C- terminal part of GLAST or GLT-1) (E and G).
Nuclei were stained with DAPI (B, D, F, H).
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to normal astrocytes (Table 2). Importantly, the use of a
specific inhibitor of EAATs (i.e. L-trans-Pyrrolidine-2,4-
dicarboxylic acid or PDC at 100 μM) confirmed the
dependency of the uptake of glutamate to EAATs both in
normal astrocytes and STTG-1 cells. The measurement of
the secretion of L-glutamate showed that STTG-1 cells
but not normal astrocytes were able to secrete L-glutamate
through Xc
- activity as demonstrated by the inhibition of
the transport by sulfasalazine (250 μM) (Table 2). As a
consequence of the defect of EAATs activity and of the
increased activity of Xc
-, we found that STTG-1 cells were
responsible for a net secretion of L-glutamate whereas
normal astrocytes were responsible of a net absorption of
glutamate (Table 3).
Localization of EAATs in non-astrocytoma human cancer
cells
The cellular localization of EAATs was then studied in
various human non-astrocytoma cancer cells listed in
Table 1. We first used sub-confluent cells at 1 or 2 days
post seeding. Immunofluorescence microscopy showed
that in all human cancer cells tested EAATs were
mostly located in the nucleus (Figure 4 and 5). As for
STTG-1 cells, changing the primary and secondary anti-
bodies did not affect the labelling demonstrating that
the observed mislocalization was not an artefact due to
antibodies (data not shown).
Cell fractionation (Figure 6) and transport studies
(Tables 2 and 3) confirmed that EAATs were mostly
mislocalized in all sub-confluent human cancer cells
tested, all cancer cells, being unable to absorb L-gluta-
mate and being responsible instead of a net secretion of
it, due to the nuclear localization of EAATs.
The cell confluence corrects the mislocalization of EAATs
in all human cancer cells, except astrocytoma
Since previous publication has demonstrated that con-
fluent Caco-2 cells absorb L-glutamate through EAATs
activity [18], we decided to study the effect of the cellu-
lar confluence on the mislocalization of EAATs in
human cancer cells. Cells were left for 7-10 days to
obtain full confluence. Immunofluorescence microscopy
showed that in all human cancer cells tested, except
astrocytoma cells, cell contact caused the relocalization
of EAATs out of the nuclei (Figure 5 and 7). Among
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Figure 2 Immunostaining of EAATs in sub-confluent primary
astrocytes. A- Primary astrocytes were labelled for EAAT1/GLAST or
EAAT2/GLT-1. B- The percentage of the EAATs signal that co-
localised with DAPI in normal astrocytes and STTG-1 cells was
quantified using ImageJ as explained in Materials and Methods.
Results obtained by quantification of at least 20 different cells were
expressed as means ± standard deviation (SD). Bars without a
common letter differ by at least p < 0.05.
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Figure 3 Cell fractionation of primary and malignant
astrocytes. Sub-confluent primary astrocytes and STTG-1 cells were
subjected to cell fractionation and western-blot analysis as
explained in Materials and Methods. Nitrocellulose membranes were
probed with antibodies directed against EAAT1/GLAST or EAAT2/
GLT-1 or against antigens specific of each compartment (i.e. Hsp90,
EGF-R and Histone 3 for the cytosolic, membrane and nuclear
fractions, respectively). Cy = cytosolic fraction, Mb = membrane
fraction, Nu = nuclear fraction.
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Page 5 of 11the human cells tested, only Caco-2 undergoes cell dif-
ferentiation after confluence, whereas all the other retain
their undifferentiated status even after full confluence.
Since EAATs relocalization was observed with all
human cancer cells tested, except astrocytoma cells, it
suggested that the cell differentiation was not involved
in such process. To confirm that the relocalization of
EAATs observed after 7 to 10 days was not linked to
cell ages, we also seeded cells at high density in order to
reach confluence faster, i.e. in 1-2 days. Similar relocali-
zation of EAATs in all cancer cells tested except astro-
cytoma cells were obtained, suggesting that the
phenomena was only dependent of cell confluence and
cell-cell contacts (data not shown).
In order to confirm immunostaining results, the trans-
port of L-glutamate by sub-confluent and fully confluent
cells were compared (Tables 2 and 3). Results of uptake
measurements showed that all human cell lines tested,
except STTG-1, became able to absorb L-glutamate
after cell confluence. Restored absorption was dependent
of EAATs as demonstrated by the inhibitory effect of
PDC. This observation confirmed the immunostaining
results and demonstrated that in all human cancer cells
tested, except astrocytoma, cell contact caused the func-
tional relocalization of EAATs at the plasma membrane.
As a consequence of the restoration of the EAATs activ-
ity, all confluent human cancer cells, except STTG-1,
became responsible for a net absorption of L-glutamate
(Table 3).
The relocalization of EAATs induced by cell contact
was finally demonstrated using cell fractionation and
western-blot analysis (Figure 6). The cell contact trig-
gered the relocalization of part of the EAATs from the
nuclear fraction to the membrane fraction in all the
human cancer cells tested except astrocytoma.
Discussion
Alterations of the handling of L-glutamate by astrocyto-
mas are linked to major consequences on cancer
growth, invasiveness and resistance to conventional
Table 2 Uptake and secretion of L-glutamate by human cancer cells and rat astrocytes.
Glutamate uptake Glutamate secretion
Sub-confluent cells Confluent cells Sub-confluent cells Confluent cells
control +PDC control +PDC control +Sulfa control +Sulfa
AGS 1.2 ± 2.7 0.7 ± 1.9 89 ± 15.2 1.9 ± 3.3 18 ± 4.7 0.9 ± 2.3 0.1 ± 0.9 1.2 ± 0.7
Caco-2 1.7 ± 1.9 0.8 ± 2.4 133 ± 19 0.8 ± 1.1 21 ± 1.8 1.1 ± 0.7 0.7 ± 1.3 1.4 ± 0.9
HeLa 6.1 ± 9.1 0.3 ± 2.2 92 ± 21 2.1 ± 0.9 24 ± 9.1 1.0 ± 0.8 0.9 ± 1.1 1.1 ± 0.8
HOG 1.7 ± 3.2 0.8 ± 0.9 86 ± 9.8 1.3 ± 2.4 19 ± 3.7 0.7 ± 1.3 0.4 ± 1.9 0.9 ± 1.2
HT29 0.8 ± 1.5 0.5 ± 2.1 121 ± 8.7 1.7 ± 3.1 27 ± 3.4 0.8 ± 1.9 0.3 ± 1.4 0.1 ± 1.9
SHSY5Y 18.4 ± 9.9 0.7 ± 2.8 84 ± 14 0.9 ± 2.3 14 ± 3.1 1.1 ± 2.4 0.1 ± 0.8 0.3 ± 2.1
STTG-1 1.6 ± 0.7 0.3 ± 1.3 2.1 ± 1.1 0.7 ± 0.9 34 ± 5.6 0.2 ± 1.2 42 ± 11 1.1 ± 0.7
Astrocytes 119 ± 12 1.5 ± 8.4 145 ± 27 0.9 ± 2.7 0.1 ± 0.3 0.0 ± 1.9 0.4 ± 1.2 0.1 ± 0.9
The uptake and the secretion of L-glutamate were measured as explained in Materials and Methods. Results were expressed as nmole of L-glutamate transported
per mg of cellular proteins. Inhibitors used were PDC (100 μM) and sulfasalazine (250 μM). All results were obtained from three independent experiments and
were expressed as means ± standard deviation (S.D). Values in bold are statistically different from the control values with p at least < 0.05.
Table 3 Net transport of L-glutamate by human cancer cells and rat astrocytes.
Sub-confluent cells Confluent cells
control + PDC + Sulfa control + PDC + Sulfa
AGS + 32 (± 15) + 39 (± 21) - 9.1 (± 13) - 74 (± 6.1) + 41 (± 18) - 81.2 (± 8.4)
Caco-2 + 36 (± 26) + 44 (± 18) - 4.5 (± 9.2) - 69.9 (± 9.6) + 42 (± 12) -72.6 (± 9.6)
HeLa + 27 (± 12) + 39 (± 9.8) - 7.8 (± 11) - 63.2 (± 5.8) + 47 (± 18) - 69.1 (± 5.2)
HOG + 37 (± 9.6) + 41 (± 12) - 2.3 (± 3.4) - 68.4 (± 9.4) + 52 (± 17) -71.7 (± 6.8)
HT29 + 48 (± 14) + 51 (± 7.5) - 5.4 (± 9.1) - 64.1 (± 14) + 49 (± 9.8) - 69.8 (± 5.9)
SHSY5Y + 15 (± 9.9) + 34 (± 6.4) - 13 (± 6.8) - 74 (± 1.8) + 48 (± 13) - 79.2 (± 9.4)
STTG-1 + 52 (± 24) + 62 (± 13) - 6.9 (± 3.4) + 69 (± 12) + 74 (± 9.5) - 9.1 (± 7.9)
Astrocytes - 79 (± 2.1) + 14 (± 10.9) - 82 (± 3.4) - 91.7 (± 2.7) + 21 (± 12) - 95.6 (± 9.1)
Net transport of L-glutamate was measured as explained in Materials and Methods. Results were expressed as variations of the extracellular concentration of L-
glutamate after 6 h of incubation at 37°C. Initial concentration of L-glutamate in cell medium was 100 μM. Positive and negative variation values corresponded
to net secretion and absorption of L-glutamate, respectively. Inhibitors used were PDC at 100 μM and sulfasalazine at 250 μM. All results were obtained from
three independent experiments and were expressed as means of the variation (in μM) ± standard deviation (S.D). Values in bold are statistically different from
the control values with p at least < 0.05.
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Page 6 of 11treatments [4-7]. Indeed, whereas normal astrocytes are
responsible for a net absorption of L-glutamate, malig-
nant astrocytes secrete high levels of glutamate at the
vicinity of the tumor. Such aberrant handling of
glutamate by astrocytomas is related to an increase in
the secretion of glutamate through the cystine/glutamate
exchanger Xc
- and a decrease in its absorption through
the glutamate transporters EAATs. Pioneer studies have
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Figure 4 Immunostaining of EAATs in sub-confluent human cancer cells. Sub-confluent human cancer cells were labelled for EAAT1/GLAST
or EAAT2/GLT-1. Nuclei were stained with DAPI.
Varini et al. Journal of Biomedical Science 2012, 19:10
http://www.jbiomedsci.com/content/19/1/10
Page 7 of 11demonstrated that the compromised uptake of gluta-
mate by astrocytoma cells is due to a nuclear mislocali-
zation of the EAATs [13]. Thus, whereas EAATs are
expressed at the plasma membrane of normal astrocytes,
the transporters are associated to the nuclei in malig-
nant astrocytes [13]. Due to the major role of extracellu-
lar glutamate on astrocytoma biology, strategies have
been developed to tackle the cancer at this level. Thus,
in vitro and in vivo experiments have demonstrated that
blocking the activity of Xc
- and/or the receptors of glu-
tamate, could reduce the growth, the invasiveness and/
or the resistance to conventional treatments of astrocy-
tomas [7,15]. However, no strategies have been devel-
oped to correct the defect of glutamate uptake observed
in human astrocytomas. One reason of this could be the
fact that, at present, the mechanism responsible for the
mislocalization of EAATs in malignant astrocytes is not
identified.
Although EAATs are also expressed in non-astrocy-
toma cancers [18,19] and that alterations of the handling
of L-glutamate have been observed in non-brain cancers
[19], no one have looked at the cellular localisation of
EAATs in non-astrocytoma cancers.
We found that EAATs are mislocalised in all sub-con-
fluent human cancer cells originated from different tis-
sues that we tested. Thus, EAATs are associated with
the nuclei not only in human astrocytoma cells but also
in human neuroblastoma, oligodendrocytoma and ade-
nocarcinoma (from intestine, stomach or genital tract)
cells. The mislocalization of EAATs in all sub-confluent
human cells tested was first demonstrated by immuno-
fluorescence microscopy and was furthermore confirmed
by cell fractionation and by transport studies. This result
demonstrates for the first time that the mislocalization
of EAATs and the associated alteration of handling of
glutamate are not restricted to astrocytoma cells and are
observed in many other human malignant cells.
Importantly, we found that the cell confluence corrects
the mislocalization of EAATs in all human cancer cells
tested except astrocytoma cells. Thus, immunofluores-
c e n c em i c r o s c o p yo b s e r v a t i o n sd e m o n s t r a t e dt h a tc e l l
confluence causes the relocalization of the EAATs signal
out of the nuclei in adenocarcinoma, oligodendrocytoma
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Figure 5 Quantification of the nuclei-associated EAATs signal
in sub-confluent and confluent human cancer cells. Sub-
confluent (white bars) and confluent (dark bars) human cancer cells
were labelled for EAAT1/GLAST or EAAT2/GLT-1. The percentage of
the GLAST (A) or GLT-1 (B) signal that co-localised with DAPI was
quantified using ImageJ as explained in Materials and Methods.
Results obtained by quantification of at least 20 different cells were
expressed as means ± standard deviation (SD). Statistical difference
between sub-confluent and confluent cells was evaluated using t-
test with * p < 0.05 and ** p < 0.01.
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Figure 6 Cell fractionation of sub-confluent and confluent
human cancer cells. Astrocytoma brain cancer (STTG-1),
adenocarcinoma (Caco-2) and non-astrocytoma brain cancer (SH-
SY5Y and HOG) cells were used. Sub-confluent and confluent
human cancer cells were subjected to cell fractionation and
western-blot analysis as explained in Materials and Methods.
Nitrocellulose membranes were probed with antibodies directed
against GLAST or Histone 3. Cy = cytosolic fraction, Mb =
membrane fraction, Nu = nuclear fraction. Similar results were
obtained with antibodies directed against GLT-1 (data not shown).
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Page 8 of 11and neuroblastoma, but not in astrocytoma cells. Cell
fractionation and western-blot analysis confirmed immu-
nofluorescence observations. Functional expression of
EAATs at the plasma membrane was furthermore
confirmed by transport studies that showed that, after
cell confluence, all human cell lines tested became able
to absorb L-glutamate whereas astrocytoma cells still
secreted it.
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Figure 7 Immunostaining of EAATs in confluent human cancer cells. Confluent human cancer cells were labelled for EAAT1/GLAST or
EAAT2/GLT-1. Nuclei were stained with DAPI.
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vations already suggest that modifications of the handling
of L-glutamate by malignant cells could have implications
in the biology (growth, invasiveness and resistance to
treatment) of cancers other than astrocytomas as pre-
viously suggested by others [19]. Importantly, it was
recently confirmed by silencing the expression of selected
glutamate receptors that extracellular glutamate modulates
the growth of non-astrocytoma cancer cells [24].
Although no EAATs mislocalization should be found
in vivo in well developed/confluent non-astrocytoma
human tumors, altered glutamate handling could be
hypothetically found when non-astrocytoma cancer cells
are not fully confluent, i.e. very early during tumor for-
mation and/or when malignant cells leave the solid
tumor as metastasis. Future studies using non-astrocy-
toma human malignant tissues at different stages of
tumor growth should confirm our hypothesis.
The fact that EAATs are relocalized after cell conflu-
ence, at least in human non-astrocytoma cells, suggests
that a cell-cell contact event triggers such phenomena.
Future studies based on the comparison of cellular
events caused by cell contact in human non-astrocytoma
and astrocytoma cells should help characterising the
membrane-associated molecules (protein(s) and/or lipid
(s)) responsible for the correction. Interestingly, it has to
be noted that mutations of the cadherin-related tumor
suppressor homolog precursor also known as FAT
tumor suppressor is frequently found in human astrocy-
tomas [25]. Based on the cell surface expression of cad-
herins and their role in cell-cell contacts, such protein
will be a good candidate.
Conclusions
Taken together, our results demonstrated that the mis-
localization of EAATs, initially observed with human
astrocytomas, is not limited to this cancer type and hap-
pens in many others malignant cells, underlying a
potential role of altered glutamate handling in those
cancers, as described for astrocytomas. In addition, our
results demonstrated that a cell-cell contact corrects the
mislocalization of EAATs in all human cancer cells
tested, except astrocytoma, suggesting that the cell con-
tact-dependent signal allowing EAATs relocalization is
absent in astrocytomas.. Identification and correction of
this signal deficient in astrocytoma will potentially lead
to the elaboration of new therapeutic strategies to cor-
rect EAATs defect and glutamate handling in astrocy-
toma depriving the tumor of the extracellular glutamate
that is essential for its growth, invasion and resistance.
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